These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
271 related articles for article (PubMed ID: 24445497)
21. Endoglin-targeted cancer therapy. Seon BK; Haba A; Matsuno F; Takahashi N; Tsujie M; She X; Harada N; Uneda S; Tsujie T; Toi H; Tsai H; Haruta Y Curr Drug Deliv; 2011 Jan; 8(1):135-43. PubMed ID: 21034418 [TBL] [Abstract][Full Text] [Related]
22. TGF-β & BMP receptors endoglin and ALK1: overview of their functional role and status as antiangiogenic targets. Jonker L Microcirculation; 2014 Feb; 21(2):93-103. PubMed ID: 25279424 [TBL] [Abstract][Full Text] [Related]
23. Tolerability of first-line therapy for metastatic renal cell carcinoma. Porta C; Szczylik C Cancer Treat Rev; 2009 May; 35(3):297-307. PubMed ID: 19249157 [TBL] [Abstract][Full Text] [Related]
24. Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer. Wagner AD; Thomssen C; Haerting J; Unverzagt S Cochrane Database Syst Rev; 2012 Jul; (7):CD008941. PubMed ID: 22786517 [TBL] [Abstract][Full Text] [Related]
25. Bevacizumab in non small cell lung cancer. Sandler A Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4613-6. PubMed ID: 17671151 [TBL] [Abstract][Full Text] [Related]
26. Interleukin-8 as a modulator of response to bevacizumab in preclinical models of head and neck squamous cell carcinoma. Gyanchandani R; Sano D; Ortega Alves MV; Klein JD; Knapick BA; Oh S; Myers JN; Kim S Oral Oncol; 2013 Aug; 49(8):761-70. PubMed ID: 23623402 [TBL] [Abstract][Full Text] [Related]
27. A Phase I/biomarker study of bevacizumab in combination with CNTO 95 in patients with advanced solid tumors. Uronis HE; Jia J; Bendell JC; Howard L; Ready NA; Lee PH; Starr MD; Dellinger A; Pang H; Nixon AB; Hurwitz HI Cancer Chemother Pharmacol; 2015 Feb; 75(2):343-52. PubMed ID: 25527204 [TBL] [Abstract][Full Text] [Related]
28. Phase I and Preliminary Phase II Study of TRC105 in Combination with Sorafenib in Hepatocellular Carcinoma. Duffy AG; Ma C; Ulahannan SV; Rahma OE; Makarova-Rusher O; Cao L; Yu Y; Kleiner DE; Trepel J; Lee MJ; Tomita Y; Steinberg SM; Heller T; Turkbey B; Choyke PL; Peer CJ; Figg WD; Wood BJ; Greten TF Clin Cancer Res; 2017 Aug; 23(16):4633-4641. PubMed ID: 28465443 [No Abstract] [Full Text] [Related]
29. Angiogenesis inhibition in the treatment of lung cancer. Vokes E; Herbst R; Sandler A Clin Adv Hematol Oncol; 2006 Nov; 4(11 Suppl 23):1-10; quiz 11-2. PubMed ID: 17143257 [TBL] [Abstract][Full Text] [Related]
30. Biomarkers of anti-angiogenic therapy in metastatic colorectal cancer (mCRC): original data and review of the literature. Pohl M; Werner N; Munding J; Tannapfel A; Graeven U; Nickenig G; Schmiegel W; Reinacher-Schick A Z Gastroenterol; 2011 Oct; 49(10):1398-406. PubMed ID: 21964893 [TBL] [Abstract][Full Text] [Related]
31. Monoclonal antibodies targeting epidermal growth factor receptor and vascular endothelial growth factor with a focus on head and neck tumors. Caponigro F; Formato R; Caraglia M; Normanno N; Iaffaioli RV Curr Opin Oncol; 2005 May; 17(3):212-7. PubMed ID: 15818163 [TBL] [Abstract][Full Text] [Related]
32. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Jain RK; Duda DG; Clark JW; Loeffler JS Nat Clin Pract Oncol; 2006 Jan; 3(1):24-40. PubMed ID: 16407877 [TBL] [Abstract][Full Text] [Related]
33. Endoglin Targeting: Lessons Learned and Questions That Remain. Liu Y; Paauwe M; Nixon AB; Hawinkels LJAC Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33375670 [TBL] [Abstract][Full Text] [Related]
34. EGFR- and VEGF(R)-targeted small molecules show synergistic activity in colorectal cancer models refractory to combinations of monoclonal antibodies. Poindessous V; Ouaret D; El Ouadrani K; Battistella A; Mégalophonos VF; Kamsu-Kom N; Petitprez A; Escargueil AE; Boudou P; Dumont S; Cervera P; Fléjou JF; André T; Tournigand C; Chibaudel B; de Gramont A; Larsen AK Clin Cancer Res; 2011 Oct; 17(20):6522-30. PubMed ID: 21880790 [TBL] [Abstract][Full Text] [Related]
35. Emerging therapies for metastatic colorectal cancer: focus on EGFR and VEGF inhibition. Venook AP J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S74-84. PubMed ID: 19780248 [TBL] [Abstract][Full Text] [Related]
36. Bevacizumab: a treatment option for recurrent glioblastoma multiforme. Buie LW; Valgus J Ann Pharmacother; 2008 Oct; 42(10):1486-90. PubMed ID: 18765835 [TBL] [Abstract][Full Text] [Related]
38. Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide. Takahashi N; Haba A; Matsuno F; Seon BK Cancer Res; 2001 Nov; 61(21):7846-54. PubMed ID: 11691802 [TBL] [Abstract][Full Text] [Related]
39. Bevacizumab combination therapy: a review of its use in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. Dhillon S BioDrugs; 2013 Aug; 27(4):375-92. PubMed ID: 23728884 [TBL] [Abstract][Full Text] [Related]
40. Yeast-derived beta-glucan augments the therapeutic efficacy mediated by anti-vascular endothelial growth factor monoclonal antibody in human carcinoma xenograft models. Salvador C; Li B; Hansen R; Cramer DE; Kong M; Yan J Clin Cancer Res; 2008 Feb; 14(4):1239-47. PubMed ID: 18281559 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]